Integrated stepped alcohol treatment for patients with HIV and at-risk alcohol use: a randomized trial

Table 2 Past 6 month receipt of alcohol treatment medications at baseline and follow-up by treatment group

Medication, n (%)	Integrated stepped alcohol treatment (n = 47)	Treatment as usual (n = 46)	p value
Any alcohol treatment medication^a
Baseline	5 (10.6)	10 (21.7)	0.15
Week 24	8 (17.0)	11 (23.9)	0.41
Week 52	5 (10.6)	6 (13.0)	0.72
Disulfiram
Baseline	0 (0)	0 (0)	NA
Week 24	0 (0)	0 (0)	NA
Week 52	0 (0)	0 (0)	NA
Acamprosate
Baseline	0 (0)	0 (0)	NA
Week 24	0 (0)	0 (0)	NA
Week 52	0 (0)	0 (0)	NA
Naltrexone
Baseline	0 (0)	0 (0)	NA
Week 24	1 (2.1)	1 (2.2)	0.99
Week 52	1 (2.1)	0 (0)	0.99
Topiramate
Baseline	0 (0)	0 (0)	NA
Week 24	0 (0)	0 (0)	NA
Week 52	0 (0)	0 (0)	NA
Baclofen
Baseline	1 (2.1)	2 (4.4)	0.62
Week 24	2 (4.3)	2 (4.4)	0.99
Week 52	2 (4.3)	1 (2.2)	0.99
Gabapentin
Baseline	4 (8.5)	8 (17.4)	0.20
Week 24	6 (12.8)	8 (17.4)	0.53
Week 52	4 (8.5)	5 (10.9)	0.74

^aBased on receipt of disulfiram, acamprosate, naltrexone, topiramate, baclofen and/or gabapentin

ISSN: 1940-0640